Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acorn Cardiovascular Inc.

This article was originally published in Start Up

Executive Summary

Acorn Cardiovascular Inc. has developed a device for the treatment of congestive heart failure. It operates under the same theory as cardiac wrapping, but is less invasive and less costly. Acorn's "jacket" made of synthetic fibers surrounds the heart and constrains it, preventing the cascade of progressive enlargement and weakening that accompanies CHF. According to Acorn's president and CEO Donald G. Rohrbaugh, the jacket's fibers are knitted into a unique configuration designed to conform closely to the heart's exterior. Special compliance properties provide uniform contact so that there are no particular stress points. During implantation, the device is tailored to provide a 5% reduction in the diameter of the heart. That reduction immediately helps to absorb some of the stress in the heart's wall and allows the myocardium to recover. "It's like providing an elastic sock on a tired leg muscle," says Rohrbaugh. "It absorbs some of those fatiguing stresses, and when the myocardium recovers, the heart is able to improve its contractility and relaxation properties so that it pumps more efficiently."

You may also be interested in...



Paracor: Can a Mechanical Device Treat Heart Failure?

Heart failure is a huge growing market in which devices are looking to succeed where drugs have provided only limited benefit. Paracor is taking on the role of David In a field dominated by the Goliaths in cardiac rhythm management and their powered devices. The company is betting that its strategy to focus first on a mechanical approach offers a better alternative for many patients not well-served by current therapies.

Cardiovascular devices

Two areas of heart disease in want of therapeutic solutions are attracting device innovation: atrial fibrillation and congestive heart failure. Successful developers will be rewarded by large markets with little in terms of current competition.

Upgraded Paige Suite Gains CE-IVD and UKCA Marks

Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel